Streetbeat News

Products Services

BLDP

CP

Ballard Power Systems (NASDAQ:BLDP) has received an order for additional fuel cell engines from Canadian Pacific Kansas City (CPKC, NYSE:CP). The eighteen 200 kW fuel cell engines, planned for delivery in 2023, will support the expansion of CPKC's Hydrogen Locomotive Program. Over the past two years, Ballard has supplied CPKC with 20 fuel cell engines for use in three different types of locomotives. The success of these trials has resulted in the significant expansion of the original hydrogen locomotive program.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:34 pm

LPCN

META

STM

Lipocine Inc. (LPCN) reported positive results from its Phase 2 study for patients with cirrhosis. Meta Platforms (META) reported Q2 earnings per share of $2.98, beating estimates, and sales of $32.00B, also beating estimates. STMicroelectronics (STM) revised its FY23 revenues outlook to $17.25B-$17.55B, from prior $17.0B-$17.8B, versus $17.3B estimate.

Portfolio Pulse from ryanfaloona@benzinga.com

July 27, 2023 | 12:34 pm

AMZN

CVLT

Commvault has expanded its partnership with Amazon Web Services (AWS) through AWS ISV Workload Migration and Service Ready Programs. This inclusion will accelerate customers' cloud migration and provides assurance that Commvault's Backup & Recovery solution has been validated by AWS Partner Solution Architects.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 12:33 pm

MOB

Mobilicom Limited (NASDAQ:MOB) has announced design win sales into three new geographic markets: Korea, Brazil, and Canada. This includes orders for its MCU Maxi Controller PRO and SkyHopper Datalinks. These orders bring Mobilicom's design wins to a total of 48 as of June 30, 2023. Each design win represents initial sales of Mobilicom's systems and components to be integrated into new autonomous systems designed by manufacturers of drones and robotics. These design wins are expected to lead to commercial scale orders.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:33 pm

ATXI

Avenue Therapeutics, Inc. (NASDAQ:ATXI) has announced that the first patient has been dosed in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA). AJ201 is currently the lead drug candidate in the clinic for SBMA and enrollment in the trial is expected to be complete by the end of 2023 or early 2024 with potential topline data in 2024. The trial aims to demonstrate how AJ201's novel, multi-fold mechanism of action reduces accumulation of mutant AR aggregates to potentially decrease neuroinflammation, protect cells from oxidative stress, and ultimately, improve clinical outcomes for SBMA patients.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:32 pm

UPXI

Upexi has implemented the Re:Amaze artificial intelligence tool to enhance the online experience for its customers. The tool is expected to improve customer service and engagement.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 12:28 pm

AAPL

COIN

FB

GOOGL

HON

MCD

Investor sentiment declines after the Fed raises interest rates by 0.25%. McDonald's, Meta Platforms, and three other stocks are highlighted as ones to watch. Ark Invest continues to sell shares of Warren Buffett-backed BYD and trims Coinbase holdings. Crypto regulations are closer than ever as the US House panel approves two bills. Apple's iPhone 15 Pro Max may have a $1,299 price tag. Google's early lead puts Alphabet ahead of Microsoft in the AI race. European automakers are forming partnerships in China to conquer the booming EV market. Honeywell is likely to report higher Q2 earnings.

Portfolio Pulse from Akanksha Bakshi

July 27, 2023 | 12:17 pm

BIOR

Biora Therapeutics, Inc. (NASDAQ:BIOR) announced positive results from its clinical device performance study for its NaviCap targeted oral delivery platform. The study evaluated the device function and safety, with the device accurately identifying entry into the colon and achieving distribution throughout the colon in all subjects. The company plans to proceed toward an IND application in the third quarter of this year for its BT-600 program for treatment of ulcerative colitis.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:13 pm

ELYS

Elys Game Technology has been granted a Class III Contractor license by the Three Affiliated Tribes Gaming Commission to provide sports betting services to the 4 Bears Casino & Lodge in North Dakota. The company's subsidiary, Elys Gameboard Technologies, will provide sports betting technology and bookmaking services, representing the company's plans to expand its Elys America brand and sportsbook products throughout the U.S. and Canada.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:13 pm

ROIV

Telavant, a Roivant company, has initiated a Phase 2 clinical trial of RVT-3101 for the treatment of moderate to severely active Crohn's disease. This follows Roivant's recent announcement of favorable results from a Phase 2b study of RVT-3101 in ulcerative colitis. The TAHOE study will evaluate the safety and efficacy of RVT-3101 in patients with Crohn's disease.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 12:11 pm